1
Will precision therapies fail at the point of delivery?
The most ambitious biomedical work now turns on whether immune and genome-engineering tools can reach the right cells safely and for long enough.
NeuroImmunology brings the nervous system into the same engineering conversation as genetic medicine. Recent selections point to complement-targeted therapeutics in neurological disease, immune activity around the skull, and blood-brain barrier mechanisms as treatment problems, not only discovery science.
Genetic Engineering Publications adds the delivery question. A Nature guide to newer genome editors and a mouse-model study using in vivo base editing both move the focus from editing as a concept to where, when and how a biological program reaches cells.
The overlap is practical. A selection on CAR-T therapy for glioblastoma frames the tumor microenvironment as something that has to be disarmed, while blood-brain barrier work shows why access to the nervous system remains a central bottleneck. Precision is no longer just a molecular claim; it is an anatomical one.
Together these topics show biomedical science narrowing the gap between immune mechanisms and programmable interventions. The promise is more exact treatment; the risk is that the hardest step sits after the target has been found.
Further reading